33 results match your criteria: "Institut Paoli-Calmettes Cancer Center[Affiliation]"
Urol Pract
November 2024
Englander Institute for Precision Medicine, Meyer Cancer Center, Weill Cornell Medicine, New York Presbyterian Center, New York, New York.
Introduction: No consensus exists on performance standards for evaluation of generative artificial intelligence (AI) to generate medical responses. The purpose of this study was the assessment of Chat Generative Pre-trained Transformer (ChatGPT) to address medical questions in prostate cancer.
Methods: A global online survey was conducted from April to June 2023 among > 700 medical oncologists or urologists who treat patients with prostate cancer.
Eur Urol
October 2024
Onkozentrum Zurich, University of Zurich and Tumorzentrum Hirslanden Zurich, Zurich, Switzerland.
World J Urol
September 2024
Department of Urology, Université de Paris, APHP, Saint Louis Hospital, Paris, France.
Purpose: To report the oncological outcomes and the tolerance between 6 instillations and more than 6 cycles of hyperthermic intravesical chemotherapy(HIVEC) in patients with non-muscle invasive bladder cancer(NMIBC).
Methods: This is a multicenter retrospective study from a national database including 9 expert centers. All patients treated with HIVEC between 2016 and 2023 for NMIBC were included.
Eur Urol Open Sci
August 2024
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Background And Objective: Building on previous research demonstrating better prostate cancer (PC) diagnostics via a biomarker-enhanced approach, this study focuses on cost analysis of PC care using the Stockholm3 test. We assessed the economic impact in European health care systems using real-world evidence for diagnostic outcomes and relevant costs.
Methods: We evaluated two PC diagnostic strategies: (1) the conventional prostate-specific antigen (PSA) strategy with magnetic resonance imaging (MRI) and (2) PSA testing with a reflex to biomarkers at PSA ≥1.
Eur Urol
September 2024
Division of Surgery & Interventional Science, University College London, London, UK; Department of Urology, University College London Hospital NHS Foundation Trust, London, UK.
Background And Objective: The Prostate Cancer Radiological Estimation of Change in Sequential Evaluation (PRECISE) recommendations standardise the reporting of prostate magnetic resonance imaging (MRI) in patients on active surveillance (AS) for prostate cancer. An international consensus group recently updated these recommendations and identified the areas of uncertainty.
Methods: A panel of 38 experts used the formal RAND/UCLA Appropriateness Method consensus methodology.
Eur Urol Oncol
October 2024
Department of Urinary and Vascular Imaging, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France; LabTau, INSERM Unit 1032, Lyon, France; Université Lyon 1, Université de Lyon, Lyon, France. Electronic address:
Background And Objective: Prostate multiparametric magnetic resonance imaging (MRI) shows high sensitivity for International Society of Urological Pathology grade group (GG) ≥2 cancers. Many artificial intelligence algorithms have shown promising results in diagnosing clinically significant prostate cancer on MRI. To assess a region-of-interest-based machine-learning algorithm aimed at characterising GG ≥2 prostate cancer on multiparametric MRI.
View Article and Find Full Text PDFEur Urol
June 2024
CHU Pointe-a-Pitre Abymes, Pointe-a-Pitre Abymes, France.
Minerva Urol Nephrol
February 2024
Department of Urology, Institut Paoli-Calmettes Cancer Center, Marseille, France.
Prostate imaging techniques have progressed across the years allowing for a better detection and characterization of prostate cancer (PCa) lesions. These advancements have led to the possibility to also improve and tailor the treatments on the most aggressive lesion, defined as Index Lesion (IL), to reduce morbidity. The IL is, indeed, considered as the entity which encompass the most aggressive features in prostate cancer disease.
View Article and Find Full Text PDFCancers (Basel)
July 2023
Department of Urology, Cantonal Hospital Aarau, 5001 Aarau, Switzerland.
Robot-assisted radical cystectomy with intracorporeal urinary diversion (iRARC) is increasingly being performed instead of open surgery. A criticism of this technique is the long learning curve, but limited data are available on this topic. At our center, the transition from open radical cystectomy (ORC) to iRARC began in May 2017.
View Article and Find Full Text PDFWorld J Urol
September 2023
Department of Urology, CHU Montpellier, Montpellier, France.
Purpose: To evaluate the feasibility, safety, and early oncologic outcomes after post-chemotherapy robot-assisted retroperitoneal lymph node dissection (PC-RARPLND) for metastatic germ cell tumors (mGCT).
Methods: We retrospectively analyzed patients from four tertiary centers who underwent PC-RARPLND for mGCT, from 2011 to 2021. Previous treatment of mGCT, intraoperative and postoperative complications, and early oncologic outcomes were assessed.
Cancers (Basel)
February 2023
Department of Surgical Oncology 2, Institut Paoli-Calmettes Cancer Center, 13009 Marseille, France.
CIS of the bladder is associated with a high risk of progression. In the case of BCG failure, radical cystectomy should be performed. For patients who refuse or are ineligible, bladder-sparing alternatives are evaluated.
View Article and Find Full Text PDFWorld J Urol
November 2023
Department of Urology, Université de Paris, APHP, Saint Louis Hospital, Paris, France.
World J Urol
February 2023
Department of Urology, CHU Bordeaux, Bordeaux, France.
Purpose: To describe clinical features of patients with oncocytoma on renal biopsy (RMB), correlation with final histology on surgically treated patients, and predictive factors of discrepancy between RMB and final histology.
Methods: This was a retrospective study conducted in the framework of the UroCCR project (NCT03293563). All tumors with oncocytoma on RMB were selected and all pathological reports were reviewed.
Arch Ital Urol Androl
December 2022
Department of Urology, Institut Paoli-Calmettes Cancer Center, Marseille.
Prog Urol
November 2022
Department of Urology, Bicêtre Hospital, 63, rue Gabriel-Péri, 94270 Le Kremlin-Bicêtre, France. Electronic address:
If surgical treatment of urinary stones is indicated, the urologist has now different modalities depending on each situation. This includes extracorporeal lithotripsy, ureteroscopy (rigid and flexible), and percutaneous nephrolithotomy. Ureteroscopy is also performed for diagnostic purposes, and for the treatment of upper urinary tract tumors.
View Article and Find Full Text PDFMinerva Urol Nephrol
December 2023
Department of Urology, Institut Paoli Calmettes Cancer Center, Marseille, France.
Background: Data is lacking about long-term impact of JJ stents (JJst) on renal parenchyma. The aim of the study was to assess the evolution of renal parenchyma in patients with JJst indwelling for more than two years, and to find predictive factors for the development of renal atrophy.
Methods: Consecutive patients with JJst indwelled for more than 24 months, with a history of cancer, were retrospectively included.
Cancer Discov
October 2022
Gustave Roussy, Villejuif, France.
Eur J Nucl Med Mol Imaging
August 2022
Department of Urology, Skåne University Hospital, Malmö, Sweden.
Eur Urol Oncol
October 2022
Department of Urology, Skåne University Hospital, Malmö, Sweden; Department of Translational Medicine, Medical Faculty, Lund University, Lund, Sweden. Electronic address:
Background: Prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) is useful for selected clinical indications in patients with prostate cancer (PCa) but it may have broader clinical utility owing to the emergence of lutetium-177-PSMA-617 ([Lu]Lu-PSMA) therapy. However, robust data regarding the impact of PSMA PET/CT on patient management and treatment are lacking, and in many areas, the role of next-generation imaging has not been defined.
Objective: To assess expert opinion on the use of PSMA-based imaging and therapy to develop interim guidance.
World J Urol
March 2023
Department of Urology, Institut Paoli-Calmettes Cancer Center, Marseille, France.
Purpose: Prostate cancer (PCa) imaging has been revolutionized by the introduction of multi-parametric Magnetic Resonance Imaging (mpMRI). Transrectal ultrasound (TRUS) has always been considered a low-performance modality. To overcome this, a computerized artificial neural network analysis (ANNA/C-TRUS) of the TRUS based on an artificial intelligence (AI) analysis has been proposed.
View Article and Find Full Text PDFClin Genitourin Cancer
August 2022
Department of Urology, Institut Paoli-Calmettes Cancer Center, Marseille, France.
Introduction: Multiparametric MRI (mpMRI) has become the standard imaging technique for the diagnosis of prostate cancer. However, mpMRI pathways are depending on experience, expertise, and information transfer from radiology to urology. Micro-ultrasound (Micro-US) is a new system, using high frequency (up to 29 MHz) and high resolution (down to 75 µm) ultrasound images.
View Article and Find Full Text PDFInt J Hyperthermia
December 2021
Department of Surgical Oncology 2, Institut Paoli Calmettes Cancer Center, Marseille, France.
Purpose: To evaluate Hyperthermic-Intra-Vesical Chemotherapy (HIVEC) efficacy regarding 1-year disease-free survival (RFS) rate and bladder preservation rate in patients with High-risk Non-Muscle Invasive Bladder Cancer (NMIBC) who fail BCG therapy or are contraindicated to BCG.
Methods: Between June 2016 and October 2019, patients treated with HIVEC for mostly high-risk NMIBC who failed BCG or BCG-naive if BCG contraindicated have been included in our study. These patients had a theoretical indication for cystectomy but were ineligible for surgery or refused it.
Eur Urol Oncol
June 2021
Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Context: Management of newly diagnosed prostate cancer (PCa) is guided in part by accurate clinical staging. The role of imaging, including magnetic resonance imaging (MRI) and positron emission tomography/computed tomography (PET/CT), in initial staging remains controversial.
Objective: To systematically review the studies of MRI and/or PET/CT in the staging of newly diagnosed PCa with respect to tumor (T), nodal (N), and metastatic (M) staging (TNM staging).
Objective: In gynecologic oncology, minimally invasive surgery using conventional laparoscopy (CL) decreases the incidence of severe morbidity compared to open surgery. In 2005, robot-assisted laparoscopy (RL) was approved for use in gynecology in the US. This study aimed to assess whether RL is superior to CL in terms of morbidity incidence.
View Article and Find Full Text PDFEur J Surg Oncol
March 2016
Department of Surgery, Institut Paoli Calmettes Cancer Center, 232, Boulevard Sainte-Marguerite, 13273 Marseille, France. Electronic address:
Background: Two options are possible for the management of early stage cervical cancer, without lymph node involvement: radical surgery or brachytherapy followed by surgery. The aim of this study was to compare overall survival (OS) and disease-free survival (DFS) of early stage cervical cancers managed by uterovaginale brachytherapy followed by extrafasciale hysterectomy (group 1) or by radical hysterectomy alone (group 2). The secondary objectives were to compare the morbidity of these two different approaches and to evaluate the parametrial involvement rate in patients managed by radical hysterectomy.
View Article and Find Full Text PDF